Agreement is Largest Commitment to EVO ICL™ in
the U.S.
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of the EVO family of Implantable
Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia,
today announces another milestone achieved on its U.S. Highway 93
go-to-market program – a strategic agreement with IQ Laser Vision,
a leader in providing clear vision to clients with locations across
California and Texas, and a top EVO ICL practice in North
America.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240507036972/en/
Tom Frinzi, Chair of the Board, President
and CEO, STAAR Surgical (Left) and Dr. Robert T. Lin, founder and
surgeon, IQ Laser Vision (Right). (Photo: Business Wire)
IQ Laser Vision will make EVO ICL lenses a primary option for
patients seeking surgical vision correction within the range of -3D
to -20D, as part of its comprehensive refractive offering. IQ Laser
Vision intends to nearly double its volume in EVO ICLs over the
course of the next 12 months. To support the transition and ramp
up, STAAR Surgical and IQ Laser Vision will collaborate on
marketing, education, practice development and clinical support
activities to further elevate awareness of EVO ICL and
substantially increase the availability of the lenses to all
qualified patients across the IQ Laser Vision Family of Practices,
which includes Scott Hyver Visioncare, Ellis Eye, and Mattioli
Vision Professionals.
Tom Frinzi, Chair of the Board and CEO of STAAR Surgical,
stated, “With the rapid growth of EVO ICL in the U.S., against the
backdrop of a continued decline in laser vision correction
procedures, it’s becoming clear that lens-based procedures like EVO
ICL are the future of refractive vision correction. STAAR Surgical
made a strategic pivot late last year to shape that future – with a
program that works double-duty to accelerate growth in leading
EVO-ready practices, while working alongside them to test, learn
and invest in the strategic drivers of that growth. Today, we’re
thrilled to announce that IQ Laser Vision has joined our U.S.
Highway 93 program with the largest agreement for EVO ICL in the
U.S. thus far. Dr. Lin is a renowned leader and pioneer in
refractive eye surgery having performed over 70,000 refractive
procedures and is one of the most experienced ICL surgeons in North
America, having implanted over 1,000 ICLs over the past 12 months.
Dr. Lin’s deep and expansive expertise across refractive surgery
makes his decision to offer EVO ICL as a primary option now all the
more meaningful.”
Corneal laser-based refractive procedures, like LASIK and SMILE,
work by removing corneal tissue to thin and reshape the cornea to
correct a patient’s vision. EVO ICL is a lens-based refractive
procedure, which works by implanting a lens in the eye to correct a
patient’s vision while preserving the cornea. Both lens and
laser-based methods are safe and effective and have their place in
a comprehensive refractive offering. EVO delivers excellent visual
results across a broad range of correction with built-in UV
protection and proven long-term stability. Further, EVO is a
reversible lens implant, allowing surgeons to future-proof a
patient’s eyes if age-related vision correction is needed down the
road.
“At the IQ Laser Vision Family of Practices, our mission has
always been to transform lives by delivering clear vision, and we
are extremely grateful to have helped many patients including our
own family members, celebrities, and athletes achieve that
transformation,” said Robert T. Lin, MD, founder and surgeon, IQ
Laser Vision. “Refractive practices are at a critical juncture –
with interest in corneal-based laser procedures waning, and contact
lens- and eyeglass-wearers reluctant to commit to a more permanent
solution – it’s time to consider a new path forward.”
Dr. Lin continued, “While studies show that refractive vision
correction may be safer than long-term use of contact lenses,
patients have been shying away from corneal-based laser vision
correction (such as LASIK) due to a variety of factors. I believe
EVO ICL is a way to re-invigorate the refractive surgery category
as a whole. With surgeons across Europe and Asia using EVO ICL
across the diopter range, and many offering ICL as the first-line
treatment, it’s clear to me that we need to get the word out in the
U.S. I am grateful to STAAR for recognizing this immense need, and
working with us as we help patients achieve their dream of visual
freedom.”
For more information about EVO Implantable Collamer® Lenses,
please visit https://evoicl.com.
References
- EVO/EVO+ ICL DFU and PIB.
- Martinez-Plaza E, Lopez-Miguel A, Lopez-De La Rosa A, et al.
Effect of the EVO+ Visian Phakic Implantable Collamer Lens on
Visual Performance and Quality of Vision and Life, Am J Ophthalmol
2021;226: 117–125.
- Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid
Measurements as Dry-Eye Score in Patients After LASIK and ICL
Surgery. Presented at American Society of Cataract and Refractive
Surgery (ASCRS) 2012.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures and markets
implantable lenses for the eye. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small
incision. STAAR’s lens used in refractive surgery is called an
Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™
product line. More than 3,000,000 ICLs have been sold to date and
STAAR markets these lenses in over 75 countries. To learn more
about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
About IQ Laser Vision
Established in 1999 by Dr. Robert T. Lin, IQ Laser Vision is
recognized as the most experienced EVO ICL and ZEISS SMILE vision
correction center in North America. It has formed esteemed
partnerships with Mattioli Vision Professionals, Scott Hyver Vision
Care, and Ellis Eye by IQ Laser Vision, collectively known as the
IQ Laser Vision Network. These collaborations underscore its
commitment to ophthalmological excellence. The team at IQ Laser
Vision consists of board-certified surgeons with a collective
experience exceeding 60 years, having successfully completed over
300,000 vision correction procedures. The clinic's state-of-the-
art facilities are equipped with the latest eye care technology,
including the advanced ArcScan Technology. With 18 locations across
major U.S. cities including Los Angeles, Irvine, San Francisco, San
Jose, and Houston, IQ Laser Vision ensures comprehensive
accessibility to its services. For more information or to book a
free consultation, please visit the company’s website at
iqlaservision.com.
Important Safety Information for EVO
ICL
The EVO Visian ICL lens is intended to correct/reduce
nearsightedness between -3.0 D up to -20.0 D and treat astigmatism
from 1.0 D to 4.0 D. If you have nearsightedness within these
ranges, EVO Visian ICL surgery may improve your distance vision
without eyeglasses or contact lenses. Because the EVO Visian ICL
corrects for distance vision, it does not eliminate the need for
reading glasses, you may require them at some point, even if you
have never worn them before. Since implantation of the EVO Visian
ICL is a surgical procedure, before considering EVO Visian ICL
surgery you should have a complete eye examination and talk with
your eye care professional about EVO Visian ICL surgery, especially
the potential benefits, risks, and complications. You should
discuss the time needed for healing after surgery. Complications,
although rare, may include need for additional surgical procedures,
inflammation, loss of cells from the back surface of the cornea,
increase in eye pressure, and cataracts. You should NOT have EVO
Visian ICL surgery if your doctor determines that 1) the shape of
your eye is not appropriate, 2) you do not meet the minimum
endothelial cell density for your age at the time of implantation,
3) you have moderate to severe glaucoma, 4) your vision is not
stable; or 5) if you are pregnant or nursing.
For additional information with potential benefits, risks and
complications please visit evoicl.com.
Safe Harbor
All statements that are not statements of historical fact are
forward-looking statements, including statements about any of the
following: any financial projections (including sales), plans,
strategies, and objectives of management for 2024 and beyond or
prospects for achieving such plans, expectations for sales,
revenue, margin, expenses or earnings, and any statements of
assumptions underlying any of the foregoing, including those
relating to financial performance in the upcoming quarter, fiscal
year 2024 and beyond. Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements include risks and uncertainties related
to global economic conditions, as well as the factors set forth in
the Company’s Annual Report on Form 10-K for the year ended
December 29, 2023 under the caption “Risk Factors,” which is on
file with the Securities and Exchange Commission and available in
the “Investor Information” section of the company’s website under
the heading “SEC Filings.” We disclaim any intention or obligation
to update or revise any financial projections or forward-looking
statement due to new information or events. These statements are
based on expectations and assumptions as of the date of this press
release and are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those
described in the forward-looking statements. The risks and
uncertainties include the following: global economic conditions;
the impact of COVID-19; the discretion of regulatory agencies to
approve or reject existing, new or improved products, or to require
additional actions before or after approval, or to take enforcement
action; international trade disputes and substantial dependence on
demand from Asia; and the willingness of surgeons and patients to
adopt a new or improved product and procedure.
We intend to use our website as a means of disclosing material
non-public information and for complying with our disclosure
obligations under Regulation FD. Such disclosures will be included
on our website in the ‘Investor Relations’ sections. Accordingly,
investors should monitor such portions of our website, in addition
to following our press releases, SEC filings and public conference
calls and webcasts.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507036972/en/
Investors & Media Brian Moore Vice President,
Investor Relations and Corporate Development (626) 303-7902, Ext.
3023 bmoore@staar.com
Grafico Azioni STAAR Surgical (NASDAQ:STAA)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni STAAR Surgical (NASDAQ:STAA)
Storico
Da Dic 2023 a Dic 2024
